Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma

Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma
CME, CPE, CNE
James O. Armitage, MD; John P. Leonard, MD; and Jason Westin, MD, MS, FACP
 
Release Date: November 30, 2022
Expiration Date: November 30, 2023

In this activity, three experts discuss the spectrum of care for patients with diffuse large B-cell lymphoma (DLBCL). Dr. Armitage will begin by reviewing the history of treatment advances and the new classification of DLBCL. Dr. Leonard will discuss current data regarding investigational frontline therapies. Lastly, Dr. Westin will describe new targets and novel therapies in relapsed/refractory disease and beyond. This program concludes with an in-depth discussion on applying this information to current practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group.
Begin, Earn CreditView Only, No Credit

© 2024 MediCom Worldwide, Inc. All rights reserved